Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer
Laura Valerio , Antonio Matrone
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002291
Multikinase inhibitors (MKIs) and highly selective tyrosine kinase inhibitors (HS-TKIs) positively impact the progression-free survival (PFS) of locally advanced and metastatic thyroid cancer cases. Moreover, disease-specific survival (DSS) and overall survival (OS) improvements were observed in some instances, suggesting a general benefit in disease control. In advanced and metastatic thyroid cancers, other conventional treatments are often ineffective when surgery cannot be performed due to the extension of the disease and/or the invasion of vital neck structures (such as the larynx, trachea, esophagus, recurrent laryngeal nerve, and carotid artery). In these cases, systemic treatments with MKIs and HS-TKIs have recently been evaluated for their potential to block tumor growth and reduce tumor size to make surgery possible or improve the control of metastatic disease. The study aimed to evaluate the performance of these systemic drugs in the neoadjuvant treatment of thyroid cancer patients, focusing on their efficacy according to the different histology.
Tyrosine kinase inhibitors / neoadjuvant treatment / thyroid cancer / targeted therapy / unresectable thyroid cancer
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
Ark N, Zemo S, Nolen D, Holsinger FC, Weber RS. Management of locally invasive well-differentiated thyroid cancer. Surg Oncol Clin N Am. 2008; 17: 145-55, ix. |
| [5] |
Schlumberger M, Tahara M, |
| [6] |
|
| [7] |
|
| [8] |
Filetti S, Durante C, Hartl DM, Leboulleux S, Locati LD, Newbold K, |
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, |
| [50] |
|
| [51] |
Minna E, Brich S, Todoerti K, Pilotti S, Collini P, Bonaldi E, |
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) v5. 0. Cancer Ther Eval Progr. 2017; 155. |
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
Sanabria A, Ferraz C, |
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
Iwasaki H, Toda S, Ito H, Nemoto D, Murayama D, Okubo Y, |
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
Matrone A, Gambale C, Prete A, Cappagli V, Lorusso L, Bottici V, |
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
/
| 〈 |
|
〉 |